Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kadar Moideen

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|October 22, 2015
Impaired Cytokine but Enhanced Cytotoxic Marker Expression in Mycobacterium tuberculosis-Induced CD8+ T Cells in Individuals With Type 2 Diabetes and Latent Mycobacterium tuberculosis InfectionNathella Pavan Kumar, Kadar Moideen, Parakkal Jovvian George, et al.
Cytokine|December 8, 2019
Heightened systemic levels of anti-inflammatory cytokines in pulmonary tuberculosis and alterations following anti-tuberculosis treatmentKadar Moideen, Nathella P Kumar, Ramalingam Bethunaickan, et al.
Tuberculosis (Edinburgh, Scotland)|August 21, 2019
Diminished type 1 and type 17 cytokine expressing - Natural killer cell frequencies in tuberculous lymphadenitisGokul Raj Kathamuthu, Nathella Pavan Kumar, Kadar Moideen, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|May 17, 2021
Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidityNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
The Journal of Infection|October 9, 2016
Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factorsNathella Pavan Kumar, Kadar Moideen, Shanmugam Sivakumar, et al.
Plos One|November 15, 2018
Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitisGokul Raj Kathamuthu, Kadar Moideen, Vaithilingam V Banurekha, et al.
Plos One|September 15, 2017
Heightened circulating levels of antimicrobial peptides in tuberculosis-Diabetes co-morbidity and reversal upon treatmentNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
Tuberculosis (Edinburgh, Scotland)|November 21, 2016
Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatmentNathella Pavan Kumar, Kadar Moideen, Shanmugam Sivakumar, et al.
Cytokine|October 30, 2016
Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1β and IL-18 in tuberculous lymphadenitisGokul Raj Kathamuthu, Kadar Moideen, Dhanaraj Bhaskaran, et al.
Immunity, Inflammation and Disease|September 30, 2015
IL-27 and TGFβ mediated expansion of Th1 and adaptive regulatory T cells expressing IL-10 correlates with bacterial burden and disease severity in pulmonary tuberculosisNathella P Kumar, Kadar Moideen, Vaithilingam V Banurekha, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|October 22, 2015
Impaired Cytokine but Enhanced Cytotoxic Marker Expression in Mycobacterium tuberculosis-Induced CD8+ T Cells in Individuals With Type 2 Diabetes and Latent Mycobacterium tuberculosis InfectionNathella Pavan Kumar, Kadar Moideen, Parakkal Jovvian George, et al.
Cytokine|December 8, 2019
Heightened systemic levels of anti-inflammatory cytokines in pulmonary tuberculosis and alterations following anti-tuberculosis treatmentKadar Moideen, Nathella P Kumar, Ramalingam Bethunaickan, et al.
Tuberculosis (Edinburgh, Scotland)|August 21, 2019
Diminished type 1 and type 17 cytokine expressing - Natural killer cell frequencies in tuberculous lymphadenitisGokul Raj Kathamuthu, Nathella Pavan Kumar, Kadar Moideen, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|May 17, 2021
Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidityNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
The Journal of Infection|October 9, 2016
Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factorsNathella Pavan Kumar, Kadar Moideen, Shanmugam Sivakumar, et al.
Plos One|November 15, 2018
Altered circulating levels of B cell growth factors and their modulation upon anti-tuberculosis treatment in pulmonary tuberculosis and tuberculous lymphadenitisGokul Raj Kathamuthu, Kadar Moideen, Vaithilingam V Banurekha, et al.
Plos One|September 15, 2017
Heightened circulating levels of antimicrobial peptides in tuberculosis-Diabetes co-morbidity and reversal upon treatmentNathella Pavan Kumar, Kadar Moideen, Vijay Viswanathan, et al.
Tuberculosis (Edinburgh, Scotland)|November 21, 2016
Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatmentNathella Pavan Kumar, Kadar Moideen, Shanmugam Sivakumar, et al.
Cytokine|October 30, 2016
Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1β and IL-18 in tuberculous lymphadenitisGokul Raj Kathamuthu, Kadar Moideen, Dhanaraj Bhaskaran, et al.
Immunity, Inflammation and Disease|September 30, 2015
IL-27 and TGFβ mediated expansion of Th1 and adaptive regulatory T cells expressing IL-10 correlates with bacterial burden and disease severity in pulmonary tuberculosisNathella P Kumar, Kadar Moideen, Vaithilingam V Banurekha, et al.
Pageof 6